Soh, Y. Q., Thng, Z. X., Ngo, W. K., Tan, C. S., Lim, T. H., Lim, L. W., . . . Rajagopalan, R. (2025). Anti-VEGF treatment switch in real-world DME patients: Ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study). BMJ Publishing Group.
Chicago Style (17th ed.) CitationSoh, Yu Qiang, et al. Anti-VEGF Treatment Switch in Real-world DME Patients: Ranibizumab Versus Aflibercept for Bevacizumab DME Non-responding Patients (SWIRL Study). BMJ Publishing Group, 2025.
MLA (9th ed.) CitationSoh, Yu Qiang, et al. Anti-VEGF Treatment Switch in Real-world DME Patients: Ranibizumab Versus Aflibercept for Bevacizumab DME Non-responding Patients (SWIRL Study). BMJ Publishing Group, 2025.
Warning: These citations may not always be 100% accurate.